Boston’s biotech scene just dropped a heavy beat. Ensoma has secured $53 million in fresh funding, not to pad the balance sheet but to push genomic medicine out of theory and into the clinic. Founded in 2019 out of the 4:59 Initiative at 5AM Ventures, Ensoma didn’t tiptoe out of stealth in 2021; it walked out loud with a $70 million Series A. That was followed by an $85 million Series B in early 2023, extended by $50 million later that year. Stack it all up with this latest round, and they’ve raised about $258 million. In a capital market where investors are handing out nickels like they’re hundred-dollar bills, that level of commitment is its own proof of concept.
Gilead Sciences led the round and claimed a board seat, joined by an ensemble of names that don’t waste their time on science fiction: 5AM Ventures, Catalio Capital Management, Cormorant Asset Management, Delos Capital, F-Prime, the Gates Foundation, Hanwha Impact Partners, Mirae Asset Financial Group, Qatar Investment Authority, RTW, Solasta Ventures, SymBiosis, and Viking Global Investors. The investor roster alone reads like a biotech festival lineup where every act is a headliner.
CEO Jim Burns, Ph.D., who came aboard in 2024 after steering Locanabio and Casebia Therapeutics and holding senior posts at Genzyme and Sanofi, is driving Ensoma’s transition into a clinical-stage company. Chairman Paula Soteropoulos, who has more than three decades of biopharma leadership, backs the play with experience spanning IPOs to exits. Scientific co-founders Dr. Hans-Peter Kiem and Dr. André Lieber bring the academic firepower, while Chief Scientific Officer Robert Peters, Ph.D., Chief Technology Officer Daniel Leblanc, and Vice President of Clinical Development Andrew Dietz, M.D., MSCR, round out a leadership team that knows how to take therapies from bench to bedside without missing a beat.
The company’s lead program, EN-374, is the first in vivo hematopoietic stem cell-directed gene insertion therapy cleared by the FDA. With both Rare Pediatric Disease and Orphan Drug designations secured, and its Phase 1/2 trial in X-linked chronic granulomatous disease now open, Ensoma is chasing impact where current options fall short. The Engenious platform that powers it all isn’t science fiction; it’s an engineered delivery system built on virus-like particles with 35 kilobase payload capacity. No stem cell collection, no harsh conditioning, just direct edits that turn once-complex treatments into outpatient possibilities.
Add in a $1.25 billion strategic collaboration with Takeda and a scalable suspension manufacturing process that’s already proven, and you see why this round matters. Ensoma isn’t just “in the body,” as its name suggests. With capital, science, and conviction aligned, it’s carving its place in the bloodstream of biotech itself.
